BIOGEN INC
BIIBNASDAQ🏆 #345 by market capEarnings Oct 29Biotech
$204.00▼ $3.10 (−1.52%)
Market closed · at close1h—
24h▼ 1.5%
7d▼ 1.3%
14d▼ 2.5%
30d▼ 2.5%
1y▲ 58.3%
🏦Market Cap
$30.14B
Mid Cap
📈Revenue Growth (YoY)
+0.3%
Slowing
📊Gross Margin
74.0%
High
💵FCF Margin
25.3%
Strong
⚖️P/S Ratio
3.1x
Fair
Otter Score
45
Weak
📊
Analyst Ratings
Price
$204.00
Total
48
Raised
7
Lowered
7
Avg PT
$234.60
H / L
$300 / $157
| Institution | Action | Rating | Date |
|---|---|---|---|
Mizuho | Reiterated | Outperform | 2026-08-04 |
Citigroup | Reiterated | Neutral | 2026-08-03 |
HC Wainwright & Co. | Reiterated | Buy | 2026-07-30 |
Morgan Stanley | Reiterated | Equal Weight | 2026-07-30 |
TD Cowen | Reiterated | Buy | 2026-07-30 |
RBC Capital | Reiterated | Outperform | 2026-07-30 |
Wedbush | Reiterated | Neutral | 2026-07-30 |
Canaccord Genuity | Reiterated | Buy | 2026-07-30 |
UBS | Reiterated | Buy | 2026-07-30 |
Barclays | Reiterated | Equal Weight | 2026-07-29 |
Guggenheim | Reiterated | Buy | 2026-07-21 |
B of A Securities | Reiterated | Neutral | 2026-07-21 |
Truist Securities | Upgraded | Hold → Buy | 2026-07-13 |
Needham | Reiterated | Buy | 2026-06-29 |
Piper Sandler | Reiterated | Overweight | 2026-05-15 |
Wells Fargo | Upgraded | Equal Weight → Overweight | 2026-04-20 |
Oppenheimer | Reiterated | Outperform | 2026-04-01 |
HSBC | Reiterated | Reduce | 2026-03-17 |
Freedom Broker | Reiterated | Hold | 2026-02-23 |
BMO Capital | Reiterated | Market Perform | 2026-02-09 |
JP Morgan | Reiterated | Neutral | 2026-02-09 |
Stifel | Upgraded | Hold → Buy | 2025-11-06 |
Bernstein | Reiterated | Market Perform | 2025-11-03 |
Baird | Reiterated | Outperform | 2025-05-02 |
Goldman Sachs | Reiterated | Buy | 2025-04-23 |
Argus Research | Downgraded | Buy → Hold | 2025-04-04 |
Scotiabank | Reiterated | Sector Outperform | 2025-02-13 |
Jefferies | Downgraded | Buy → Hold | 2024-12-09 |
Cantor Fitzgerald | Reiterated | Overweight | 2024-09-09 |
Raymond James | Upgraded | Market Perform → Outperform | 2023-12-07 |
Atlantic Equities | Reiterated | Neutral | 2023-08-08 |
Cowen & Co. | Reiterated | Outperform | 2023-02-16 |
SVB Leerink | Reiterated | Outperform | 2022-10-26 |
William Blair | Upgraded | Market Perform → Outperform | 2021-06-08 |
Credit Suisse | Reiterated | Outperform | 2021-02-04 |
DZ Bank | Upgraded | Hold → Buy | 2020-11-10 |
SunTrust Robinson Humphrey | Reiterated | Buy | 2020-04-23 |
Nomura | Reiterated | Buy | 2020-02-07 |
Standpoint Research | Downgraded | Buy → Hold | 2019-11-01 |
Piper Jaffray | Downgraded | Overweight → Neutral | 2019-06-28 |
Stifel Nicolaus | Downgraded | Buy → Hold | 2019-02-21 |
Argus | Downgraded | Buy → Hold | 2018-02-16 |
H.C. Wainwright | Reiterated | Buy | 2018-01-26 |
Bank of America | Reiterated | Buy | 2017-10-18 |
Leerink Swann | Downgraded | Outperform → Market Perform | 2017-03-16 |
PiperJaffray | Upgraded | Neutral → Overweight | 2016-11-07 |
Deutsche Bank | Reiterated | Buy | 2014-07-24 |
FBR Capital | Reiterated | Outperform | 2013-10-02 |
One row per institution, most recent rating